Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2019
|
| gptkbp:approvedBy |
gptkb:European_Union
|
| gptkbp:ATCCode |
A16AX15
|
| gptkbp:compatibleWith |
gptkb:United_States
|
| gptkbp:developer |
gptkb:Akcea_Therapeutics
gptkb:Ionis_Pharmaceuticals |
| gptkbp:form |
solution for injection
|
| gptkbp:genericName |
gptkb:volanesorsen
|
| https://www.w3.org/2000/01/rdf-schema#label |
Waylivra
|
| gptkbp:indication |
rare genetic lipid disorder
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
antisense oligonucleotide inhibitor of APOC3
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:reduces |
triglyceride levels
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
thrombocytopenia
injection site reactions |
| gptkbp:target |
APOC3 mRNA
|
| gptkbp:usedFor |
gptkb:familial_chylomicronemia_syndrome
|
| gptkbp:bfsParent |
gptkb:Ionis_Pharmaceuticals
|
| gptkbp:bfsLayer |
6
|